Melo D R, Lundgren D L, Muggenburg B A, Guilmette R A
Inhalation Toxicology Research Institute, Lovelace Biomedical and Environmental Research Institute, Albuquerque, NM 87185, USA.
Health Phys. 1996 Aug;71(2):190-7. doi: 10.1097/00004032-199608000-00010.
A 6-wk study was conducted using immature (4.7 mo), young adult (2.4 y), and aged (13.5 y) male beagles to determine the modifying effect of age on the effectiveness of Prussian Blue decorporation therapy for the removal of injected 137Cs. Whole-body clearance rates for injected 137Cs decreased with increasing age in the dogs. Treatment with Prussian Blue changed the ratio of fecal to urinary 137Cs excretion from 0.8 in untreated dogs to 2.2 in treated animals. The 137Cs concentrations in tissues of untreated and Prussian Blue-treated dogs at the end of the 6-wk study were similar, with the greatest concentrations in the skeletal muscle tissue, spleen, and kidneys. There was a lower concentration of 137Cs in the livers of the treated dogs. The reductions in the average total whole-body doses resulting from Prussian Blue treatment during the course of this study were 51% in the immature, 31% in the young adult, and 38% in the aged dogs. Because of the differences in the intake of Prussian Blue by the dogs in the different groups relative to their body weight, it is unclear as to the relative effectiveness of Prussian Blue in dogs of different ages.
进行了一项为期6周的研究，使用未成熟（4.7个月）、年轻成年（2.4岁）和老年（13.5岁）雄性比格犬，以确定年龄对普鲁士蓝促排疗法清除注射的137Cs有效性的影响。犬体内注射的137Cs全身清除率随年龄增长而降低。普鲁士蓝治疗使粪便与尿液中137Cs排泄的比例从未治疗犬的0.8变为治疗动物的2.2。在6周研究结束时，未治疗和普鲁士蓝治疗犬组织中的137Cs浓度相似，骨骼肌组织、脾脏和肾脏中的浓度最高。治疗犬肝脏中的137Cs浓度较低。在本研究过程中，普鲁士蓝治疗使未成熟犬、年轻成年犬和老年犬的平均全身总剂量分别降低了51%、31%和38%。由于不同组犬相对于体重摄入普鲁士蓝的量存在差异，尚不清楚普鲁士蓝在不同年龄犬中的相对有效性。
